New partnership with Garvan Institute of Medical Research to grow clinical genomics capability
Australian Clinical Labs and the Garvan Institute of Medical Research have formed a new partnership to grow genomics research and clinical capabilities that drive the development of new forms of precision medicine.
The partnership will secure advanced genomics testing and research capabilities in Australia and continue the work previously carried out by Garvan’s Genome.One team.
The new partnership is a natural fit. Both organisations share a passion and dedication to advancing genomics research and clinical care, and both bring complementary strengths to the new arrangement.
“Clinical Labs has two leading clinical molecular genetic services, one in Victoria and the other in Western Australia. We work closely with medical practitioners to deliver precise diagnostics and personalised treatment plans, based on a patient’s genetic makeup. We have long been leaders in clinical molecular genetics in the fields of cancer, mental health, sexual health, pregnancy, genetic screening, blood disorders and drug therapy.
“Genome.One’s clinical genomic service will become part of Clinical Labs and remain located at the Garvan Institute in Sydney. We will work closely with their researchers and their sequencing team to build a bigger and more advanced Precision Medicine pathology service. In combination, our work will advance the translation of genomics research into clinical practice and strengthen our diagnostic pathology service by taking clinical learnings back to the researchers at Garvan,” said Group CEO and Managing Director at Clinical Labs, Melinda McGrath.
Genome.One’s clinical genomic service team joined Clinical Labs on Monday 26th November.
About Genomics Sequencing
Unlocking the secrets of inherited disease through advanced research has driven decades of scientific enquiry and captured the imagination of the medical and commercial investment communities.
Genomics has uncovered medical discoveries around cancer, heart conditions and numbers of rare diseases. Advanced genomics predicts an individual’s risk of developing disease based on their genetic history and predisposition. Medical practitioners use advanced genomics to develop personalised patient treatment plans. It also offers families access to advanced diagnostic services that help them understand and manage their specific needs – now and in the future.
Read more about genomics: www.genome.one